The Protein Assays Market, estimated at USD 2.80 Bn in 2025, is expected to exhibit a CAGR of 12% and reach USD 6.19 Bn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
Market Dynamics:
Rising biopharmaceutical industry: Rising demand for monoclonal antibodies and novel biologics in disease treatment boosts growth of biopharmaceutical industry. This has significantly increased demand for protein assays as sample quantification and analysis is a fundamental step during drug development and production.
Growing technological advancements: Continuous innovation and advancements in protein quantification technologies such as microfluidics-enabled assays and nanoplasmonic biosensors provide high accuracy and throughput. This has increased its adoption across various end-use industries including pharmaceutical and biotechnology companies. Introduction of tools such as microplates and robotic liquid handling have made protein assays procedures automated and less time-consuming.
Increasing focus on proteomics research worldwide can drive the market growth
Proteomics research aims to study the structure and function of proteins in biological systems. It helps in understanding various diseases at the molecular level and developing targeted therapeutics. Growing importance of proteomics in drug discovery and development can boost demand for protein assays. Various governments across the globe are increasingly funding proteomics research projects. For instance, the U.S. National Institutes of Health provides huge grants for proteomics and systems biology projects every year. Growing collaborations between pharmaceutical companies and research institutes promotes proteomics studies.
Rising R&D investment in life science industries
Protein assays have wide applications in various life science sectors such as biotechnology, pharmaceutical, diagnostic, and others. Growing R&D spending by players in these industries can drive the market growth. Pharmaceutical companies are extensively utilizing protein assays for biomarker discovery, validation of drug targets, and assessing drug responses. Biotech firms rely on these assays for protein expression analysis and purification. According to some estimates, the global expenditure on R&D in the life sciences industry will exhibit CAGR of over 5% during 2020-2025. This increasing budget allocation for R&D demonstrates ample opportunities for protein assay kit manufacturers and service providers in the near future.
Limitation of colorimetric and fluorescence-based protein assays
Colorimetric and fluorescence-based protein assays are the most commonly used quantification methods. However, these have certain limitations such as interference of assay reagents with sample components, involvement of tedious processing steps, and inadequate sensitivity for low-abundance proteins. These constraints restrict their applicability in some settings. Advanced proteomics studies often require detection of proteins present in trace amounts in complex sample matrices like blood, urine, and others. Conventional protein assays fail to quantitate such low-level analytes accurately owing to interference issues. This acts as a hindrance for their widespread adoption in modern protein analysis pipelines.
Complexity of assay method development for novel protein targets
With advances in omics technologies, new protein biomarkers and drug targets are being discovered continuously. However, it is challenging for assay developers to optimize suitable quantification methods for emergent protein analytes in a short timeframe. The lack of background information on these novel targets complicates assay method design and validation processes. It requires extensive R&D efforts to streamline protocols that can reliably detect minuscule changes in atypical protein concentrations. This technical bottleneck poses difficulties in leveraging the full potential of groundbreaking proteomics findings in diagnostics and drug development in a timely manner.
Emergence of more sensitive assay technologies
To address the limitations of conventional colorimetric and fluorescence-based protein quantitation, newer technologies with improved sensitivity are gaining traction. For example, microfluidic-based protein assays allow analysis of minute biofluid samples with higher accuracy. Nanotechnology-enabled protein detection methods employing designed nanostructures can quantitate ultralow protein amounts in complex mixtures. Mass spectrometry is also evolving as a powerful technique for absolute and relative protein quantification. Introduction of such advanced assay platforms is expected to open up new vistas by enabling comprehensive exploration of proteomes. This transitions the proteomics landscape towards more robust, high-throughput, and quantitative analysis paradigms.
Growing demand for multiplex assays
Traditional protein assays quantify a single analyte in each experimental setup. However, modern proteomics investigations often require simultaneous analysis of multiple biomarkers/targets. This generates high demand for multiplex assays that can measure multiple proteins in one analysis with high precision. Development of novelxassay platforms capable of quantifying protein panels is identified as a major opportunity area. Multiplex techniques help reduce sample volume requirements, decrease processing timelines, and improve resource efficiency as compared to single-analyte methods. These are well-aligned with the objectives of emerging applications like disease subtyping, drug response monitoring, and protein signature-based diagnostics.
Link: https://www.coherentmarketinsights.com/market-insight/protein-assays-market-1087
Key Developments:
- In June 2024, Sysmex Corporation announced the upcoming launch of the HISCL VEGF and HISCL PEDF Assay Kits for Research Use in Japan. These research reagents, designed for measuring secreted proteins in cell culture media, aim to enhance automation and efficiency in quality control testing for regenerative cellular medicine.
- In June 2023, Pixelgen Technologies, a leader in single-cell spatial proteomics, announced the commercial release of its inaugural kit. This kit utilizes the company’s proprietary Molecular Pixelation (MPX) technology for three-dimensional spatial analysis of immune cell surface proteins.
- In May 2023, 10x Genomics, Inc., a pioneer in single-cell and spatial biology, announced the commercial release of its new Visium CytAssist Gene and Protein Expression product. This addition enhances the capabilities of the Visium CytAssist for spatial analysis.
- In March 2022, Biognosys introduced an enhanced range of proteomics platforms designed to offer pharmaceutical and diagnostics clients profound biological insights throughout the entire R&D pipeline, from initial discovery stages to clinical applications
- In January 2022, Amgen formed a partnership with Generate Biomedicines to discover and develop protein therapeutics targeting five different areas across various therapeutic fields and modalities, with an initial investment exceeding USD 1.9 billion
Key Players:
Thermo Fisher Scientific, Bio-Rad Laboratories, Merck KGaA, GE Healthcare, F. Hoffmann-La Roche, BD (Becton, Dickinson and Company), Agilent Technologies, Promega Corporation, Abcam plc, PerkinElmer, Lonza, Bio-Techne, Cell Signaling Technology, Revvity, Zymo Research, Enzo Biochem, Takara Bio, Sigma-Aldrich (Merck Group), Geno Technology, and NanoString Technologies
Contact Us